Discovery of novel MDM2-targeted therapy for pediatric AML
Discovery of novel MDM2-targeted therapy for pediatric AML
Dr. Muxiang Zhou – Emory University, Atlanta, GA
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Stanford University, Stanford, CA
Polycomb inhibition sensitizes AML to anthracycline therapy
Polycomb inhibition sensitizes AML to anthracycline therapy
The Research Institute at Nationwide Children’s Hospital, Columbus, OH
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
The Regents of the University of Michigan, Ann Arbor, MI
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Baylor College of Medicine, Houston, TX
Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics
Predicting Post-Treatment Relapse in Pediatric AML Using Single-Cell Proteomics
Stanford University, Stanford, CA
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Preclinical Development of Novel Immunotherapies for Pediatric Acute Myeloid Leukemia (AML)
Children’s Hospital of Philadelphia, Philadelphia, PA
Epigenetic Therapy in AML
Epigenetic Therapy in AML
Nemours/A.I. DuPont Hospital, Wilmington, DE
Reversing NK Cell Dysfunction in Pediatric Cancer
Reversing NK Cell Dysfunction in Pediatric Cancer
Case Western Reserve University, Cleveland, OH
Zebrafish Models of Human AML
Zebrafish Models of Human AML
Dana-Farber/Harvard Medical Center, Boston, MA